UK Conditionally Approves Its First Protein-Based COVID-19 Vaccine, From Novavax

A vial of the Phase 3 Novavax COVID-19 vaccine. Alastair Grant/AP Photo

The United Kingdom has conditionally approved its first protein-based COVID-19 vaccine, made by Novavax.

The vaccine, called Nuvaxovid (generic name NVX-CoV2373), is the fifth COVID-19 vaccine authorized by the Medicines and Healthcare products Regulatory Agency (MHRA), the U.K.’s independent medicines regulator.